Arkolith/Insider Trading/COAG/Form 4

Maraganore John

DirectorHemab Therapeutics Holdings, Inc. (COAG) · full profile →Form 4 · filed May 4, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 4, 2026Conversion(C)18K——18K
May 4, 2026Conversion(C)18K——36K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 4, 2026Conversion(C)817—$00
May 4, 2026Conversion(C)817—$00
Jan 29, 2026Grant(A)107K—$0107K

Transaction Codes

C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-204048) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML